5-OMe-UDP is a potent and selective P2Y(6)-receptor agonist. 2010

Tamar Ginsburg-Shmuel, and Michael Haas, and Marlen Schumann, and Georg Reiser, and Ori Kalid, and Noa Stern, and Bilha Fischer
Department of Chemistry, Gonda-Goldschmied Medical Research Center, Bar-Ilan University, Ramat-Gan 52900, Israel.

P2Y nucleotide receptors (P2Y-Rs) play important physiological roles. However, most of the P2Y-R subtypes are still lacking potent and selective agonists and antagonists. Based on data mining analysis of binding interactions in 44 protein-uridine nucleos(t)ides complexes, we designed uracil nucleotides, substituted at the C5/C6 position. All C6-substituted derivatives were inactive at the P2Y(2,4,6)-Rs, while out of the C5-substituted analogues, only 5-OMe-UD(T)P showed activity. To rationalize the data, the ionization and conformation of these analogues were evaluated. The pK(a) values of most analogues substituted at the C5/C6 positions were unaltered compared to UTP (pK(a) 9.42), except for 5-F-UTP nucleotide (pK(a) 7.85). C6-substituted analogues adopt the syn or high-syn conformations, which are disfavored by the receptors, while 5-OMe-UD(T)P adopt the favored anti conformation. Furthermore, 5-OMe-UDP adopts the S sugar puckering, which is the conformation preferred by the P2Y(6)-R, but not the P2Y(2)- or P2Y(4)-Rs. 5-OMe-UDP fulfills the conformational and H-bonding requirements of P2Y(6)-R, thus, making a potent P2Y(6)-R agonist (EC(50) 0.08 microM), more than UDP (EC(50) 0.14 microM).

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D008968 Molecular Conformation The characteristic three-dimensional shape of a molecule. Molecular Configuration,3D Molecular Structure,Configuration, Molecular,Molecular Structure, Three Dimensional,Three Dimensional Molecular Structure,3D Molecular Structures,Configurations, Molecular,Conformation, Molecular,Conformations, Molecular,Molecular Configurations,Molecular Conformations,Molecular Structure, 3D,Molecular Structures, 3D,Structure, 3D Molecular,Structures, 3D Molecular
D009682 Magnetic Resonance Spectroscopy Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING). In Vivo NMR Spectroscopy,MR Spectroscopy,Magnetic Resonance,NMR Spectroscopy,NMR Spectroscopy, In Vivo,Nuclear Magnetic Resonance,Spectroscopy, Magnetic Resonance,Spectroscopy, NMR,Spectroscopy, Nuclear Magnetic Resonance,Magnetic Resonance Spectroscopies,Magnetic Resonance, Nuclear,NMR Spectroscopies,Resonance Spectroscopy, Magnetic,Resonance, Magnetic,Resonance, Nuclear Magnetic,Spectroscopies, NMR,Spectroscopy, MR
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014162 Transfection The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES. Transfections
D014530 Uridine Diphosphate A uracil nucleotide containing a pyrophosphate group esterified to C5 of the sugar moiety. UDP,Uridine Pyrophosphate,Diphosphate, Uridine,Pyrophosphate, Uridine
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D058910 Purinergic P2 Receptor Agonists Compounds that bind to and stimulate PURINERGIC P2 RECEPTORS. P2 Purinoceptor Agonists,Agonists, P2 Purinoceptor,Purinoceptor Agonists, P2

Related Publications

Tamar Ginsburg-Shmuel, and Michael Haas, and Marlen Schumann, and Georg Reiser, and Ori Kalid, and Noa Stern, and Bilha Fischer
October 2002, European journal of pharmacology,
Tamar Ginsburg-Shmuel, and Michael Haas, and Marlen Schumann, and Georg Reiser, and Ori Kalid, and Noa Stern, and Bilha Fischer
November 1994, European journal of pharmacology,
Tamar Ginsburg-Shmuel, and Michael Haas, and Marlen Schumann, and Georg Reiser, and Ori Kalid, and Noa Stern, and Bilha Fischer
December 1989, British journal of pharmacology,
Tamar Ginsburg-Shmuel, and Michael Haas, and Marlen Schumann, and Georg Reiser, and Ori Kalid, and Noa Stern, and Bilha Fischer
November 2007, Journal of medicinal chemistry,
Tamar Ginsburg-Shmuel, and Michael Haas, and Marlen Schumann, and Georg Reiser, and Ori Kalid, and Noa Stern, and Bilha Fischer
October 2011, The Journal of pharmacology and experimental therapeutics,
Tamar Ginsburg-Shmuel, and Michael Haas, and Marlen Schumann, and Georg Reiser, and Ori Kalid, and Noa Stern, and Bilha Fischer
August 1992, The Journal of pharmacology and experimental therapeutics,
Tamar Ginsburg-Shmuel, and Michael Haas, and Marlen Schumann, and Georg Reiser, and Ori Kalid, and Noa Stern, and Bilha Fischer
February 2001, Bioorganic & medicinal chemistry letters,
Tamar Ginsburg-Shmuel, and Michael Haas, and Marlen Schumann, and Georg Reiser, and Ori Kalid, and Noa Stern, and Bilha Fischer
April 2012, Bioorganic & medicinal chemistry,
Tamar Ginsburg-Shmuel, and Michael Haas, and Marlen Schumann, and Georg Reiser, and Ori Kalid, and Noa Stern, and Bilha Fischer
November 1993, British journal of pharmacology,
Tamar Ginsburg-Shmuel, and Michael Haas, and Marlen Schumann, and Georg Reiser, and Ori Kalid, and Noa Stern, and Bilha Fischer
July 1990, European journal of pharmacology,
Copied contents to your clipboard!